![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
COMPASSIONATE USE OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) AND RILPIVIRINE (RPV) FOR PATIENTS IN NEED OF PARENTERAL ANTIRETROVIRAL THERAPY
|
|
|
IAC 2020 July 6-10 Virtual
Reported by Jules Levin
Ronald D'Amico,1 Riya Moodley,2 Erika van Landuyt,3 Rodica Van Solingen-Ristea,3 Bryan Baugh,4 Veerle Van Eygen,3 Sherene Min,1 Annemiek de Ruiter,2
Amy Cutrell,1 Mark Shaefer,1 Caroline Foster,5 Daniella Chilton,6 Sabine Allard,7 David Margolis1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Brentford, UK; 3Janssen Pharmaceutica, Beerse, Belgium; 4Janssen Pharmaceutica, Raritan, NJ, USA; 5Imperial College NHS Healthcare Trust, London, UK; 6Guys and St Thomas NHS Healthcare Trust, London, UK; 7HIV Reference Center Universitaire Ziekenhuis Brussel, Brussels, Belgium
![0710201](../images/071120/071020-6/0710201.gif)
![0710202](../images/071120/071020-6/0710202.gif)
![0710203](../images/071120/071020-6/0710203.gif)
![0710204](../images/071120/071020-6/0710204.gif)
![0710205](../images/071120/071020-6/0710205.gif)
![0710206](../images/071120/071020-6/0710206.gif)
![0710207](../images/071120/071020-6/0710207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|